The purpose is to find out which plan keeps the cancer from getting worse for a longer time. Participants receive the assigned treatment and have regular doctor visits, scans, and questionnaires to monitor the disease, side effects, overall health, and quality of life throughout the study.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.

Participants will receive the drug once a week for the first three weeks and then every two weeks for up to 12 treatment cycles, unless the doctor decides to stop earlier. During the study, doctors will look for a complete remission, which means no signs of cancer are found, as the main sign of success, and they will also monitor overall health, side effects, and quality of life. This is a phase II trial, meaning it is an early stage study that evaluates both effectiveness and safety in a relatively small group of patients.

The aim of the trial is to see whether the new cell therapy can improve lung function better than the standard medicines. Participants are randomly assigned to one of the two groups and receive the assigned treatment through an intravenous infusion, followed by regular clinic visits over several months to check how the lungs and skin are doing. The main measurement is the change in FVC, which is the amount of air a person can exhale forcefully, and additional measurements include changes in mRSS (a score that reflects skin thickness), the percentage of predicted lung capacity (ppFVC), and the ability of the lungs to transfer oxygen (DLCO).

Participants are randomly assigned to receive either the active drug or the placebo, and neither the participants nor the study staff know which is given (double‑blind). The treatment is administered periodically over a period of about two years, with regular visits to assess thinking abilities using tools such as the MoCA test, and to monitor overall disease symptoms with scales like the MDS‑UPDRS. Safety is checked through routine lab tests, blood pressure measurements, and ECG recordings to watch for any side effects.

After a qualifying attack, participants are randomly assigned to receive either the experimental infusion or the placebo, both given through a vein. They continue the usual steroid treatment and are followed for about three months, with visits to check vision, strength, walking speed, hand dexterity, and overall disability using simple tests and questionnaires. The study records whether additional rescue treatments are needed, how quickly symptoms improve, and any side effects, allowing researchers to see if the added drug provides a meaningful benefit.

The purpose of the study is to determine whether Admilparant can be used safely over an extended period without causing serious side effects. Participants will take the medication each day and will attend regular visits where healthcare staff will check vital signs such as blood pressure and heart rate, review simple blood tests, and perform a basic heart test known as an ECG, which records the heart’s electrical activity. Any side effects that arise will be recorded and evaluated.

The study will continue for many months to gather enough information about safety and tolerability. Throughout the study, participants will be asked to report any new symptoms or problems, and they will receive routine medical check‑ups to monitor their overall health while using the medication.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.